DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02661438 (ClinicalTrials.gov)	January 12, 2016	30/12/2015	Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo	Multicenter Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation in Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB) or Chronic Obstructive Pulmonary Disease (COPD) Using Matching Placebo	Bronchiectasis;Pulmonary Disease, Chronic Obstructive	Drug: Placebo to Ciprofloxacin DPI (BAYQ3939)	Bayer	Novartis	Completed	40 Years	N/A	All	46	N/A	United States
2	NCT01764841 (ClinicalTrials.gov)	May 2, 2013	8/1/2013	Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)	Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.	Bronchiectasis	Drug: Ciprofloxacin DPI (BAYQ3939);Drug: Placebo	Bayer	Novartis	Completed	18 Years	N/A	All	416	Phase 3	United States;Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02661438
(ClinicalTrials.gov)

January 12, 2016

30/12/2015

Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo

Multicenter Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation in Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB) or Chronic Obstructive Pulmonary Disease (COPD) Using Matching Placebo

Bronchiectasis;Pulmonary Disease, Chronic Obstructive

Drug: Placebo to Ciprofloxacin DPI (BAYQ3939)

Bayer

Novartis

Completed

40 Years

N/A

All

N/A

United States

NCT01764841
(ClinicalTrials.gov)

May 2, 2013

8/1/2013

Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.

Bronchiectasis

Drug: Ciprofloxacin DPI (BAYQ3939);Drug: Placebo

Bayer

Novartis

Completed

18 Years

N/A

All

416

Phase 3

United States;Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom